Adding Hydrochlorothiazide to Olmesartan/Amlodipine Increases Efficacy in Patients With Inadequate Blood Pressure...

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Hypertension Research

Background:

• Olmesartan medoxomil/amlodipine (OLM/AML) 40/10 mg is a common treatment for hypertension.
• A significant portion of patients remain inadequately controlled on dual therapy.
• Further antihypertensive treatment strategies are needed for resistant hypertension.

Purpose of the Study:

• To evaluate the efficacy of adding hydrochlorothiazide (HCTZ) to OLM/AML 40/10 mg in patients with uncontrolled hypertension.
• To compare the effects of adding 12.5 mg and 25 mg of HCTZ.
• To assess blood pressure reduction using both seated and ambulatory blood pressure monitoring.

Main Methods:

• Randomized, parallel-group study design.
• Patients received OLM/AML 40/10 mg, with add-on HCTZ (12.5 mg or 25 mg) or continued OLM/AML alone for 8 weeks.
• Primary endpoint: change in seated diastolic blood pressure (SeDBP).
• Secondary endpoints included seated systolic BP (SeSBP) and ambulatory BP monitoring.

Main Results:

• The addition of HCTZ 25 mg resulted in a statistically significant reduction in SeDBP (-2.8 mm Hg; P<.0001).
• Both HCTZ doses led to reductions in SeSBP and improvements in ambulatory blood pressure.
• Higher rates of achieving blood pressure goals were observed with HCTZ add-on therapy.

Conclusions:

• Adding hydrochlorothiazide to olmesartan medoxomil/amlodipine is effective in further reducing blood pressure in inadequately controlled patients.
• The 25 mg dose of HCTZ provided significant additional blood pressure lowering.
• This combination therapy offers a viable option for managing resistant hypertension.